Reliever salbutamol use as a measure of exacerbation risk in chronic obstructive pulmonary disease

被引：0
作者：
Christine R. Jenkins
Dirkje S. Postma
Antonio R. Anzueto
Barry J. Make
Stefan Peterson
Göran Eriksson
Peter M. Calverley
机构：
[1] Concord Hospital,Department of Thoracic Medicine
[2] University of Sydney and The George Institute for Global Health,Department of Pulmonary Medicine and Tuberculosis
[3] University of Groningen,Pulmonary Section, Department of Medicine
[4] University Medical Center Groningen,Division of Pulmonary Sciences and Critical Care Medicine, National Jewish Health
[5] University of Texas Health Science Center,Department of Respiratory Medicine and Allergology
[6] and South Texas Veterans Health Care System,Clinical Sciences Department
[7] University of Colorado Denver School of Medicine,undefined
[8] StatMind,undefined
[9] University Hospital,undefined
[10] Institute of Ageing and Chronic Disease,undefined
[11] University Hospital Aintree,undefined
来源：
BMC Pulmonary Medicine | / 15卷
关键词：
COPD; Budesonide/formoterol; Exacerbation; Reliever medication; Predictor;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 151 条
[1]  
Vos T(2012)Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010 Lancet 380 2163-2196
[2]  
Flaxman AD(2013)Population-based burden of COPD-related visits in the ED: return ED visits, hospital admissions, and comorbidity risks Chest 144 784-793
[3]  
Naghavi M(2011)A new perspective on optimal care for patients with COPD Prim Care Respir J 20 205-209
[4]  
Lozano R(2001)Health status measurement in chronic obstructive pulmonary disease Thorax 56 880-887
[5]  
Michaud C(2011)Relationship between FEV1 change and patient-reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: a systematic review Respir Res 12 40-1327
[6]  
Ezzati M(1992)A self-complete measure of health status for chronic airflow limitation. The St. George’s Respiratory Questionnaire Am Rev Respir Dis 145 1321-469
[7]  
Yeatts KB(2008)Outcomes for COPD pharmacological trials: from lung function to biomarkers Eur Respir J 31 416-611
[8]  
Lippmann SJ(2014)Continuing to confront COPD international patient survey: methods, COPD prevalence, and disease burden in 2012–2013 Int J Chron Obstruct Pulmon Dis 9 597-8
[9]  
Waller AE(2010)Overall asthma control: the relationship between current control and future risk J Allergy Clin Immunol 125 600-323
[10]  
Hassmiller Lich K(2012)Asthma control test (ACT): comparison with clinical, functional, and biological markers of asthma control J Asthma 49 317-487
12345678910